AstraZeneca PLC · LSE:AZN

AstraZeneca — Shareholder Meeting (April 2013)

11 slides from AstraZeneca's shareholder meeting presentation, Apr 25, 2013

  1. Slide 1: AstraZeneca 2013 AGM - Chairman's remarks

    AstraZeneca 2013 AGM 25 April 2013 Chairman’s remarks Ladies and gentlemen, you elected me as a Director at last year’s AGM and it is my privilege to have served as your Chairman since last June. This is therefore the first opportunity I have had to share some thoughts with you about the first few m

  2. Slide 2: Chairman's remarks: Board commitment and industry challenges

    It is also only right that I acknowledge Simon Lowth’s role as Interim Chief Executive Officer in the months before Pascal joined us. On behalf of the whole Board, I would like to record our appreciation for his impressive leadership in this period. Supported by a highly capable and committed execut

  3. Slide 3: Chairman's remarks: strategy, dividend and share repurchases

    As far as AstraZeneca is concerned, our performance in 2012 was defined by significant revenue decline associated with the expected loss of exclusivity for several of our products. We believe these challenging market conditions will persist in 2013, including continued government interventions in re

  4. Slide 4: AstraZeneca PLC 2013 Annual General Meeting

    AstraZeneca PLC 2013 Annual General Meeting Leif Johansson Chairman

  5. Slide 5: Pascal Soriot

    Pascal Soriot Executive Director and Chief Executive Officer 16

  6. Slide 6: Simon Lowth

    Simon Lowth Executive Director and Chief Financial Officer 17

  7. Slide 7: A busy 2012 for the Board

    A busy 2012 for the Board  Management changes  Business development deals  Annual strategy update  Regular programme of meetings and activity 18

  8. Slide 8: Industry challenges

    Industry challenges • Patent expiries and competition from generics Demand side • Intensifying pricing pressures • Reward for innovation more difficult • R&D productivity challenge Supply side • Rising R&D costs • Probability of success has declined 19

  9. Slide 9: 2012 financial performance quote

    “2012 financial performance was defined by significant revenue decline associated with the loss of exclusivity for several of our products. For 2013, challenging market conditions will persist.” 20

  10. Slide 10: Dow Jones Sustainability Indexes

    Dow Jones. Sustainability Indexes Member 2012/13

  11. Slide 11: AstraZeneca PLC 2013 Annual General Meeting

    AstraZeneca PLC 2013 Annual General Meeting

AstraZeneca — Shareholder Meeting (April 2013) on 6ix